What question did this study set out to answer?

The aim is to investigate a combined treatment using EZH2 inhibition and dopamine D1 receptor activation to improve immune response in TNBC.

Dual-Target Strategy Against TNBC: EZH2 Inhibition and Dopamine D1 Activation

View Full Paper

Ask AI

Bookmark

The aim is to investigate a combined treatment using EZH2 inhibition and dopamine D1 receptor activation to improve immune response in TNBC.
Female NSG mice were implanted with MDA-MB-231 cells.
Mice were randomized into four treatment groups: vehicle, GSK126, A77636, or combination.
Treatments were administered weekly for four weeks, and tumor volume was measured.
Tumor and immune tissues were analyzed using flow cytometry.
Combination therapy significantly reduced tumor weight and volume compared to single agents.
The combination reduced Ly6C^hi monocyte infiltration by 65% and promoted Ly6C^lo accumulation.
There was a decrease in pro-inflammatory IL-1β and an increase in anti-inflammatory IL-10 signaling.

No takes yet. Share an insight, caveat, or question.

Demonstrates enhanced anti-tumor effects in triple-negative breast cancer by targeting EZH2 and dopamine D1 receptors, improving immune response.

Shukla et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Demonstrates enhanced anti-tumor effects in triple-negative breast cancer by targeting EZH2 and dopamine D1 receptors, improving immune response.